Ninety-three Chinese patients with cutaneous herpes zoster were seen during a 4-year period. Thoracic zoster occurred most commonly, followed by ophthahnic, cervical and lumbosacral zoster. Neurological complications were present in eleven patients (11.8%), the commonest being Ramsay-Hunt syndrome and segmental limb paresis. The clinical picture, pathogenesis, treatment and outcome of segmental limb paresis, myelitis and delayed contralateral hemiparesis following zoster ophthalmicus are discussed. Nine immunocompromised patients received intravenous adenine arabinoside (vidarabine) or acycloguanosine (acyclovir), and no cutaneous or visceral spread occurred in these patients,
Introduction
Herpes zoster infection is a common condition with predominantly cutaneous involvement along the dermatomes. Neurological complications beyond the posterior root ganglia and the first-order sensory neurones are infrequent. We undertook a retrospective analysis of the pattern of cutaneous involvement, the neurological complications and their outcome in 93 Chinese patients seen over a 4-year period.
Materials and methods
Patients under the care of the University Medical Unit, Queen Mary Hospital, Hong Kong between January 1981 and December 1984 with a diagnosis of herpes zoster were reviewed, with particular emphasis on the nature of any underlying disorder, the pattern of cutaneous involvement and the neurological complications. Those patients with definite motor complications were reassessed to determine their prognostic outcome. The use of intravenous adenine arabinoside (vidarabine) or acycloguanosine (acyclovir) for herpes zoster in 9 immunocompromised patients was also evaluated.
Results
Ninety-three patients were identified with a diagnosis of herpes zoster, and their age and sex distribution are shown in Figure 1 . There were 34 males and 59 females. Their median age was 57 years with a range of 13 to 96 years; 69% of them were aged 50 or above. Eighty-five patients were hospitalized on account of the herpes zoster; the other eight (8.6%) patients developed shingles while in hospital for another medical illness.
Twenty-one patients (22.6%) had underlying diseases (Table I) , mainly haematological malignancy, diabetes mellitus and systemic lupus erythematosus (SLE). Twelve of these 21 patients, including all 5 with SLE, were on steroid therapy at the time of the zoster infection.
The pattern of cutaneous involvement is shown in Table II . The thoracic dermatomes were most commonly affected, followed by the ophthalmic division of the trigeminal nerve, and the cervical and lumbosacral dermatomes. Figure 1 Age and sex distribution of 93 patients with herpes zoster; 0 male; U female.
Neurological complications occurred in 11 patients (11.8%) and the clinical data of these patients are presented in Table III . There were 3 patients with Ramsay-Hunt syndrome, 3 with segmental limb paresis, 2 with myelitis and 1 each with delayed contralateral hemiparesis, third nerve palsy and meningitis. Underlying diseases were present in 4 of these 11 patients.
The interval between the cutaneous zoster and the neurological complication ranged from simultaneous presentation to two and a half weeks, and was within one week in the majority ofcases. In no patient did the neurological complication precede the cutaneous manifestation. The neurological complication evolved Computed tomographic (CT) scan of the brain was performed in 3 patients, being normal in patient 1, with delayed contralateral hemiparesis, and patient 2, with third nerve palsy, but showing mild cerebral oedema in patient 11, who had meningitis. Cerebral angiography in the patient with delayed contralateral hemiparesis showed carotid siphon stenosis. Myelography was performed in patient 9 with acute spinal cord syndrome and this was normal. The cerebrospinal fluid (CSF) showed changes consistent with aseptic meningitis in patient 11, but was normal in the 2 patients with myelitis (patients 9 and 10) and in patient 2. Electromyographic (EMG) changes of denervation were present in all 3 patients (6, 7 and 8) with segmental limb paresis.
A 4 week course of steroid therapy was given to patient 1 with delayed contralateral hemiparesis. The other 10 patients were given supportive treatment only. They did not receive any steroid or antiviral therapy. Eight patients made a complete recovery in a period ranging from 1 week to 9 months, with the majority having recovered within 3 months. Two patients had partial recovery and one was lost to follow-up.
Intravenous vidarabine (10 mg/kg/day for one week) was given to 7 patients and intravenous acyclovir (500 mg/M2 every 8 hours for one week) to 2 patients. These 9 patients were immunocompromised 8 .6% of our patients developed zoster eruption whilst inpatients receiving specific therapy for their underlying problems. It is also interesting to note a female preponderance in our series, which probably reflects the predominance of females in our elderly population.
Motor complications are uncommon and occur in 5% of all cases of herpes zoster.3 Our higher figure of 11.8% probably reflects selection bias as patients having complications are more likely to be hospitalized. Ofcranial nerve involvement, the most widely known is the Ramsay-Hunt syndrome with facial nerve paralysis. Other cranial nerves are seldom involved.2 Third nerve palsy associated with ophthalmic zoster is a rare but well-recognized condition.4'5 '6 We encountered one case in our series. Although the associated diabetes mellitus may have caused the third nerve palsy, the temporal relationship with the infection and the pupillary involvement would favour this being a complication of ophthalmic zoster.
Segmental limb paresis occurred in 3.2% of patients in this series which is comparable to the 2.5% figure in a large series by Thomas hours of the onset of cutaneous zoster confers the greatest benefit. Our 9 immunocompromised patients were treated (7 with vidarabine and 2 with acyclovir) and none developed cutaneous or visceral spread. Specific anti-viral treatment is therefore indicated in these patients and acyclovir is preferred to vidarabine because of its greater efficacy in zoster infection23 and better solubility. Moreover, the relative lack of renal or marrow toxicity renders acyclovir particularly suitable for patients with concomitant renal or haematological diseases, although judicious use ofthis drug with appropriate dosage adjustment must be emphasized.
In immunocompetent patients, intravenous acyclovir improves the rate of cutaneous healing and decreases pain in acute zoster although it does not decrease the incidence of post-herpetic neuralgia. 24' 25 With its high cost and inconvenience of administration, routine use of intravenous acyclovir in immunocompetent subjects with herpes zoster is hard to justify. Oral acyclovir, still under clinical trial,26' 27 may, however, have a promising role in the future.
